In 2008, activating mutations in the kinase domain of the anaplastic lymphoma kinase (ALK) RTK were reported as oncogenic drivers in both sporadic and familial NB cases [8,9,10,11,12]. The gene discussed is ALK; the disease is neuroblastoma.